Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Preparing for Year Two of Part D: CMS Puts a Premium on Stability

This article was originally published in RPM Report

Executive Summary

The bids are in for insurers participating in the 2007 Medicare plan year. A last-minute rules change by CMS likely means fewer changes in the market for the second year.

You may also be interested in...



Not So Random Selection: Medicare Agency Cuts "Churn" In Part D Enrollment

One of the Obama Administration's first moves in managing the Medicare Part D benefit is to tamp down on the number of beneficiaries who will be randomly assigned to a new plan on Jan. 1. Stability is good for the program politically, but it may also be a sign of more hands-on management by the Medicare agency in the years ahead.

The Players Who Will Shape Health Care Reform in 2009

A number of key advisers will shape the health care reform debate following the Presidential Election. Here are some of the top players who will engage in the reform debate-and play important roles in health-in 2009.

Medicare Rx at a Turning Point: Big Plans Stumble as Part D Enters a Pivotal Year

United, Humana and especially WellCare are taking their licks in the run-up to the third year of the Medicare prescription drug program. That is just the latest warning sign for pharma and biotech companies that a critical market is entering a critical turning point.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS080111

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel